RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Companies Unite to Advance Regulatory Landscape of Abuse Potential Assessment

Companies Unite to Advance Regulatory Landscape of Abuse Potential Assessment

Posted 01 September 2011 | By Beatriz RochaHeddie MartynowiczRolW. UsherAndrew FriedmanJonathon ParkerRichard FanelliSuzanne Thornton-JonesCynthia AronsMark Ammann 

The US Food and Drug Administration (FDA) is collaborating with private and public stakeholders in an effort to address critical public health needs and to bridge scientific gaps.1 One of these collaborations focuses on abuse potential and involves three key groups: the Controlled Substance Staff (CSS) of FDA, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Cross Company Abuse Liability Consortium (CCALC).

 

© 2022 Regulatory Affairs Professionals Society.